Skip to content
Baret News – Lifestyle
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 2, 2026
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 21, 2026
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 6, 2026
1
2
Next Page
→